糖尿病性黄斑水肿治疗方式的研究进展  

Recent advances in new emerging therapies of diabetic macular edema

作　　者：赵子君[1] 柯晓云[1] ZHAO Zi-Jun;KE Xiao-Yun(the Department of Ophthalmology Zhujiang Hospital of Southern Medical University,Guangzhou 510000,Guangdong Province,China)

机构地区：[1]南方医科大学珠江医院眼科

出　　处：《眼科新进展》2019年第6期596-600,共5页Recent Advances in Ophthalmology

摘　　要：糖尿病性黄斑水肿为视力丧失的主要病因。当前糖尿病性黄斑水肿的治疗方法主要有抗血管内皮细胞生长因子抗体、糖皮质激素、视网膜光凝等。但仍有部分患者不应答或需反复治疗,因此需通过增加新的治疗靶点进一步完善当前治疗,其中包括抗血管内皮生长因子拮抗剂、抗血管生成素拮抗剂、Tie2受体抑制剂、激肽释放酶抑制剂、白细胞介素抑制剂、感光细胞的替换等,以期获得更好的治疗效果。Diabetic macular edema is the leading cause of visual disability.At pre-sent,the available therapeutic methods of diabetic macular edema include anti-vascular endothelial growth factor antibodies,corticosteroid,laser therapy and so on.But a number of patients do not respond or need more adequate treatment.Therefore,it is necessary to improve current therapies through new targets,such as anti-VEGF Darpin,angiopoietin antagonists,Tie2 agonists,kallikrein inhibitors,interleukin inhibitors,and photoreceptor cell replacement,in order to get better therapeutic effect.

关 键 词：糖尿病性黄斑水肿 新型治疗方法 糖尿病 

分 类 号：R774.5[医药卫生—眼科]